Biologic Therapies Approved for the Treatment of Generalized Myasthenia Gravis - Part 1
In the first episode of a two-part series, Dr. Joseph Conway will discuss four biologic therapies that have been approved in recent years by the FDA for the treatment of adults with generalized…
Read the full articleYou might also wanna read
EAN 2026: Positive trial data for cemdisiran underscores potential for use in generalized MG, says GlobalData
On June 30, at the 12th Congress of the European Academy of Neurology (EAN) 2026, Regeneron announced the results from an additional analysi
Unequal Access to New Myasthenia Gravis Therapies Across Europe Highlights Healthcare Disparities
New therapies are changing what is possible in generalised myasthenia gravis care, yet unequal access across Europe continues to hold patien
euractiv.com·21d agoEfficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis
Conditions : Autoimmune Encephalitis (AE); Autoimmune Cerebellitis Interventions : Drug: Blinatumomab Sponsors : Beijing Tiantan Hospital No
GlaxoSmithKline and Genmab submit Arzerra (Ofatumumab) application to FDA for the treatment of advanced stage blood cancer
GSK & GEN announced submission of BLA to the FD) for Arzerra to treat patients whose CLL is resistant (refractory) to previous therapies.
Megan’s Myasthenia Gravis Story: From Uncertainty to Advocacy
I was diagnosed with myasthenia gravis, or MG, in 2021 when I was in my early 20s. My journey began at a friend’s birthday party when I noti
UConn Health Minute: Managing Myasthenia Gravis
Myasthenia gravis is a chronic condition caused by the immune system attacking the body. UConn Health’s neuromuscular team has the expertise
Comments
Sign in to join the conversation.
No comments yet. Be the first.